Overview
- Construction is slated to begin in 2026 with completion targeted for 2032, according to the company.
- Lilly expects about 3,000 construction jobs and roughly 450 permanent roles for engineers, scientists, operations staff and lab technicians.
- The facility will produce small‑molecule and peptide medicines, including orforglipron, which is under FDA priority review.
- The Huntsville site was selected from more than 300 proposals, with proximity to the HudsonAlpha Institute cited for workforce training and research ties.
- It is the third of four new U.S. plants in an at‑least $27 billion expansion, with plans for AI‑enabled, automated operations and progress toward carbon neutrality.